188 related articles for article (PubMed ID: 18645606)
1. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis.
Fries W; Muja C; Crisafulli C; Costantino G; Longo G; Cuzzocrea S; Mazzon E
Int J Med Sci; 2008 Jul; 5(4):169-80. PubMed ID: 18645606
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies.
Fries W; Muja C; Crisafulli C; Cuzzocrea S; Mazzon E
Am J Physiol Gastrointest Liver Physiol; 2008 Apr; 294(4):G938-47. PubMed ID: 18258792
[TBL] [Abstract][Full Text] [Related]
3. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
4. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
5. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Centorrino T; Siriwardena AK; Cuzzocrea S
Shock; 2007 May; 27(5):542-51. PubMed ID: 17438460
[TBL] [Abstract][Full Text] [Related]
6. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha.
Mitoma H; Horiuchi T; Hatta N; Tsukamoto H; Harashima S; Kikuchi Y; Otsuka J; Okamura S; Fujita S; Harada M
Gastroenterology; 2005 Feb; 128(2):376-92. PubMed ID: 15685549
[TBL] [Abstract][Full Text] [Related]
7. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis.
Vereecke L; Sze M; Mc Guire C; Rogiers B; Chu Y; Schmidt-Supprian M; Pasparakis M; Beyaert R; van Loo G
J Exp Med; 2010 Jul; 207(7):1513-23. PubMed ID: 20530205
[TBL] [Abstract][Full Text] [Related]
8. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
Agnholt J; Dahlerup JF; Kaltoft K
Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
[TBL] [Abstract][Full Text] [Related]
10. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor alpha in T cell induced mucosal damage in the mouse intestine.
Merger M; Viney JL; Borojevic R; Steele-Norwood D; Zhou P; Clark DA; Riddell R; Maric R; Podack ER; Croitoru K
Gut; 2002 Aug; 51(2):155-63. PubMed ID: 12117872
[TBL] [Abstract][Full Text] [Related]
11. Etanercept attenuates TNBS-induced experimental colitis: role of TNF-α expression.
Paiotti AP; Miszputen SJ; Oshima CT; Artigiani Neto R; Ribeiro DA; Franco M
J Mol Histol; 2011 Oct; 42(5):443-50. PubMed ID: 21863329
[TBL] [Abstract][Full Text] [Related]
12. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit.
Grundmann S; Hoefer I; Ulusans S; van Royen N; Schirmer SH; Ozaki CK; Bode C; Piek JJ; Buschmann I
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1497-505. PubMed ID: 15923311
[TBL] [Abstract][Full Text] [Related]
14. Increased enterocyte apoptosis in inflamed areas of Crohn's disease.
Di Sabatino A; Ciccocioppo R; Luinetti O; Ricevuti L; Morera R; Cifone MG; Solcia E; Corazza GR
Dis Colon Rectum; 2003 Nov; 46(11):1498-507. PubMed ID: 14605569
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha induces apoptosis of enterocytes in mice with fulminant hepatic failure.
Song HL; Lu S; Liu P
World J Gastroenterol; 2005 Jun; 11(24):3701-9. PubMed ID: 15968724
[TBL] [Abstract][Full Text] [Related]
16. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.
Bhol KC; Tracey DE; Lemos BR; Lyng GD; Erlich EC; Keane DM; Quesenberry MS; Holdorf AD; Schlehuber LD; Clark SA; Fox BS
Inflamm Bowel Dis; 2013 Oct; 19(11):2273-81. PubMed ID: 23949620
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist.
Suominen JS; Wang Y; Kaipia A; Toppari J
Eur J Endocrinol; 2004 Nov; 151(5):629-40. PubMed ID: 15538942
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome.
Genovese T; Mazzon E; Crisafulli C; Di Paola R; Muià C; Esposito E; Bramanti P; Cuzzocrea S
Shock; 2008 Jan; 29(1):32-41. PubMed ID: 17621255
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
[TBL] [Abstract][Full Text] [Related]
20. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
